Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia
Authors' conclusion
HPT is common in patients with TIO. To avoid the occurrence of HPT in patients with TIO, timely diagnosis and tumor resection is necessary and an excessive dose of phosphate supplementation is not suggested before surgery.
Study context
- Population
- Chinese patients with tumor-induced osteomalacia (TIO)
- Participants
- 202 patients
- Outcome
- Occurrence of HPT in patients with TIO
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
HPT prevalence
Hyperparathyroidism (HPT)
91/202, 45.1%
Secondary HPT (SHPT)
84
41.6%
Tertiary HPT (THPT)
7
3.5%
Observational data: associations, not effects.
Further findings
THPT treatment
- All patients with THPT underwent parathyroidectomy; recurrence
- 1 patient
Clinical characteristics by HPT status
- SHPT vs no HPT: longer disease duration, higher rate of phosphate and calcitriol supplementation, lower serum calcium, lower urine calcium excretion, higher urine phosphate excretion
- THPT vs SHPT: even longer disease duration, higher rate of phosphate and calcitriol supplementation
Correlates of PTH
- PTH positively correlated with intact FGF23 and 1,25-dihydroxyvitamin D, not 25(OH)D
- Dose-response relationship between cumulative phosphate dose and PTH (logistic regression, restricted cubic spline)
Risk factors for HPT
- Long disease duration and phosphate supplementation independently associated with HPT
- Multivariate logistic regression
Original publication
Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia. J Clin Endocrinol Metab. Published 5 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →